genedrive plc launches new interactive investor hub
genedrive plc (AIM: GDR) Scotland national roll-out of Genedrive® MT-RNR1 ID Kit
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to note the recent media coverage of its Genedrive® MT-RNR1 ID Kit, which reduces the risk of
genedrive plc (AIM: GDR) MT-RNR1 ID Kit in Dublin’s Rotunda Hospital
Genedrive® MT-RNR1 ID Kit implemented at Dublin’s Rotunda Hospital
Genedrive Shares Jump 22% on Talks Over £1 Million Shareholder Loan
Genedrive PLC (AIM: GDR) shares soared 22% to 1.04p after the diagnostics company confirmed it is in talks with major shareholder David Nugent regarding a potential £1 million loan to
genedrive plc (AIM: GDR) Comment re: Share Price Movement
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, notes the fall in the Company’s share price on 13 August 2025 which it believes was connected to postings
genedrive PLC (AIM: GDR) Expects Revenue to Double as Commercial Momentum Builds
Genedrive PLC (AIM: GDR), the developer of rapid genetic testing technology, expects total income for the year ended 30 June to rise to around £1 million, up from £0.5 million
Genedrive PLC (AIM:GDR) received European regulatory approval
Genedrive wins EU approval for rapid genetic test aimed at stroke and heart attack care
Genedrive PLC (AIM:GDR) CYP2C19-ID Kit adopted for routine clinical use
North West Anglia Foundation NHS Trusts’ Peterborough City Hospital implements the Genedrive® CYP2C19-ID Kit for routine clinical use
Genedrive PLC (AIM:GDR) Genedrive® CYP2C19-ID Kit performance published
Superior performance to laboratory test and alternative available point of care platforms
Genedrive (AIM:GDR) shares fall 10% following CEO departure
Genedrive PLC (AIM: GDR) shares dropped 10% after the announcement that CEO James Cheek has left the company by mutual agreement.
Genedrive PLC (AIM: GDR) NICE recommends CYP2C19-ID Kit in final guidance
NICE recommends the Genedrive® CYP2C19-ID Kit in final guidance Genedrive® CYP2C19-ID test chosen as the preferred platform for point-of-care genotype testing prior to clopidogrel treatment for stroke patients in the
Genedrive PLC (AIM:GDR) Breakthrough Device Designation from the U.S. FDA
genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, is pleased to announce that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) for the Genedrive® MT-RNR1